These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 7753692)

  • 1. Bacterial resistance mechanisms to beta-lactam antibiotics: assessment of management strategies.
    Dudley M
    Pharmacotherapy; 1995; 15(1 Pt 2):9S-14S. PubMed ID: 7753692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolution of beta-lactamases.
    Bush K
    Ciba Found Symp; 1997; 207():152-63; discussion 163-6. PubMed ID: 9189640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-spectrum beta-lactamases: an actual problem of hospital microbiology (a review).
    Szabó D; Barcs I; Rozgonyi F
    Acta Microbiol Immunol Hung; 1997; 44(4):309-25. PubMed ID: 9554165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minor extended-spectrum beta-lactamases.
    Naas T; Poirel L; Nordmann P
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
    Bedenić B
    Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens.
    Helfand MS; Bonomo RA
    Curr Opin Pharmacol; 2005 Oct; 5(5):452-8. PubMed ID: 16084766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence and mechanisms of bacterial resistance in surgical infections.
    Neu HC
    Am J Surg; 1995 May; 169(5A Suppl):13S-20S. PubMed ID: 7755162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
    Bedenić B
    Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Lactam resistance and beta-lactamases in bacteria of animal origin.
    Li XZ; Mehrotra M; Ghimire S; Adewoye L
    Vet Microbiol; 2007 Apr; 121(3-4):197-214. PubMed ID: 17306475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic and clinical aspects of beta-lactam antibiotics and beta-lactamases.
    Kotra LP; Mobashery S
    Arch Immunol Ther Exp (Warsz); 1999; 47(4):211-6. PubMed ID: 10483868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.
    Bush K
    Clin Infect Dis; 2001 Apr; 32(7):1085-9. PubMed ID: 11264037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescein-labeled beta-lactamase mutant for high-throughput screening of bacterial beta-lactamases against beta-lactam antibiotics.
    Chan PH; Chan KC; Liu HB; Chung WH; Leung YC; Wong KY
    Anal Chem; 2005 Aug; 77(16):5268-76. PubMed ID: 16097768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria: current situation].
    Martínez-Martínez L; Calvo J
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():25-31. PubMed ID: 21130927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.